T. Rowe Price Associates’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

T. Rowe Price Associates’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,944	Closed	-$613K	–	2943
2023 Q2	$613K	Sell	15,944 -12,378	-44%	-$318K	﹤0.01%	2034
2023 Q1	$657K	Buy	28,322 +861	+3%	+$20.5K	﹤0.01%	1992
2022 Q4	$719K	Buy	27,461 +1,035	+4%	+$22.9K	﹤0.01%	1959
2022 Q3	$520K	Buy	+26,426	New	+$530K	﹤0.01%	2105
2021 Q4	–	Sell	-11,893	Closed	-$152K	–	3062
2021 Q3	$152K	Buy	+11,893	New	+$157K	﹤0.01%	2778
2015 Q3	–	Sell	-41,860	Closed	-$6.35M	–	2549
2015 Q2	$6.35M	Buy	+41,860	New	+$6.91M	﹤0.01%	1438

T. Rowe Price Associates's KDNY Position: Q3 2023 in Review

T. Rowe Price Associates sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 15,944 shares — an estimated $613K sold.

T. Rowe Price Associates first reported a position in KDNY in Q2 2015 and held it in 6 quarters. The position peaked at $6.35M in Q2 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

T. Rowe Price Associates reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
T. Rowe Price Associates sold 15,944 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $613K.
T. Rowe Price Associates first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
T. Rowe Price Associates's Chinook Therapeutics, Inc. Common Stock position peaked at $6.35M in Q2 2015.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.